Literature DB >> 21148225

Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.

S L Schmidt1, A M Nambiar, N Tayob, B Sundaram, M K Han, B H Gross, E A Kazerooni, A R Chughtai, A Lagstein, J L Myers, S Murray, G B Toews, F J Martinez, K R Flaherty.   

Abstract

The composite physiologic index (CPI) was derived to represent the extent of fibrosis on high-resolution computed tomography (HRCT), adjusting for emphysema in patients with idiopathic pulmonary fibrosis (IPF). We hypothesised that longitudinal change in CPI would better predict mortality than forced expiratory volume in 1 s (FEV(1)), forced vital capacity (FVC) or diffusing capacity of the lung for carbon monoxide (D(L,CO)) in all patients with IPF, and especially in those with combined pulmonary fibrosis and emphysema (CPFE). Cox proportional hazard models were performed on pulmonary function data from IPF patients at baseline (n = 321), 6 months (n = 211) and 12 months (n = 144). Presence of CPFE was determined by HRCT. A five-point increase in CPI over 12 months predicted subsequent mortality (HR 2.1, p = 0.004). At 12 months, a 10% relative decline in FVC, a 15% relative decline in D(L,CO) or an absolute increase in CPI of five points all discriminated median survival by 2.1 to 2.2 yrs versus patients with lesser change. Half our cohort had CPFE. In patients with moderate/severe emphysema, only a 10% decline in FEV(1) predicted mortality (HR 3.7, p = 0.046). In IPF, a five-point increase in CPI over 12 months predicts mortality similarly to relative declines of 10% in FVC or 15% in D(L,CO). For CPFE patients, change in FEV(1) was the best predictor of mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148225      PMCID: PMC4084829          DOI: 10.1183/09031936.00114010

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  24 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  Is idiopathic pulmonary fibrosis an environmental disease?

Authors:  Varsha S Taskar; David B Coultas
Journal:  Proc Am Thorac Soc       Date:  2006-06

3.  The clinical course of patients with idiopathic pulmonary fibrosis.

Authors:  Fernando J Martinez; Sharon Safrin; Derek Weycker; Karen M Starko; Williamson Z Bradford; Talmadge E King; Kevin R Flaherty; David A Schwartz; Paul W Noble; Ganesh Raghu; Kevin K Brown
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

Review 4.  Smoking-related interstitial lung diseases: a concise review.

Authors:  J H Ryu; T V Colby; T E Hartman; R Vassallo
Journal:  Eur Respir J       Date:  2001-01       Impact factor: 16.671

5.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Sharon Safrin; Karen M Starko; Kevin K Brown; Paul W Noble; Ganesh Raghu; David A Schwartz
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

6.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.

Authors:  Kevin R Flaherty; Adin-Cristian Andrei; Susan Murray; Chris Fraley; Thomas V Colby; William D Travis; Vibha Lama; Ella A Kazerooni; Barry H Gross; Galen B Toews; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2006-07-06       Impact factor: 21.405

7.  The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.

Authors:  Charlene D Fell; Lyrica Xiaohong Liu; Caroline Motika; Ella A Kazerooni; Barry H Gross; William D Travis; Thomas V Colby; Susan Murray; Galen B Toews; Fernando J Martinez; Kevin R Flaherty
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

8.  Clinical characteristics of combined pulmonary fibrosis and emphysema.

Authors:  Yoshiaki Kitaguchi; Keisaku Fujimoto; Masayuki Hanaoka; Satoshi Kawakami; Takayuki Honda; Keishi Kubo
Journal:  Respirology       Date:  2009-12-27       Impact factor: 6.424

9.  Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

Authors:  Jürgen Behr; Maurits Demedts; Roland Buhl; Ulrich Costabel; Richard P N Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; Francois Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; C D R Flower; Stefano Petruzzelli; Paul De Vuyst; J M M van den Bosch; Eulogio Rodriguez-Becerra; Ida Lankhorst; Marco Sardina; Gabrielle Boissard
Journal:  Respir Res       Date:  2009-10-27

10.  Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.

Authors:  V Cottin; J Le Pavec; G Prévot; H Mal; M Humbert; G Simonneau; J-F Cordier
Journal:  Eur Respir J       Date:  2009-07-30       Impact factor: 16.671

View more
  43 in total

1.  Visually stratified CT honeycombing as a survival predictor in combined pulmonary fibrosis and emphysema.

Authors:  Yong Seek Kim; Gong Yong Jin; Kum Ju Chae; Young Min Han; Su Bin Chon; Young Sun Lee; Keun Sang Kwon; Hye Mi Choi
Journal:  Br J Radiol       Date:  2015-09-21       Impact factor: 3.039

Review 2.  Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone.

Authors:  Huijin Lin; Shanping Jiang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 3.  Combined pulmonary fibrosis and emphysema syndrome: a review.

Authors:  Matthew D Jankowich; Sharon I S Rounds
Journal:  Chest       Date:  2012-01       Impact factor: 9.410

Review 4.  Combined pulmonary fibrosis and emphysema (CPFE): what radiologist should know.

Authors:  Federica Ciccarese; Domenico Attinà; Maurizio Zompatori
Journal:  Radiol Med       Date:  2016-02-19       Impact factor: 3.469

5.  Pulmonary fibrosis and emphysema: Is the emphysema type associated with the pattern of fibrosis?

Authors:  Anastasia Oikonomou; Paraskevi Mintzopoulou; Argyris Tzouvelekis; Petros Zezos; George Zacharis; Anastasios Koutsopoulos; Demosthenes Bouros; Panos Prassopoulos
Journal:  World J Radiol       Date:  2015-09-28

6.  Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?

Authors:  Karishma Hosein; Jamie Le; Marco Mura
Journal:  Lung       Date:  2016-11-17       Impact factor: 2.584

7.  The prognostic impact of combined pulmonary fibrosis and emphysema in patients with clinical stage IA non-small cell lung cancer.

Authors:  Tomoyoshi Takenaka; Kiyomi Furuya; Koji Yamazaki; Naoko Miura; Kana Tsutsui; Sadanori Takeo
Journal:  Surg Today       Date:  2017-08-18       Impact factor: 2.549

8.  The CALIPER-Revised Version of the Composite Physiologic Index is a Better Predictor of Survival in IPF than the Original Version.

Authors:  Karishma S Hosein; Gianluigi Sergiacomi; Maurizio Zompatori; Marco Mura
Journal:  Lung       Date:  2019-12-02       Impact factor: 2.584

Review 9.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

10.  Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography.

Authors:  Maurizio Zompatori; Maria Barbara Leone; Marica Giannotta; Nazzareno Galiè; Massimiliano Palazzini; Maria Letizia Bacchi Reggiani; Lea Bono; Gian Stefano Pollini
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.